Furthermore, to our knowledge, this is the first study to show that a low pre-SCT CRP level and low pre-SCT NLR are good prognostic biomarkers for the PC regimen, when it is administered as SCT after ICI treatment for R/M HNSCC. The gene discussed is CRP; the disease is head and neck squamous cell carcinoma.